New to peptides? Start with the foundations ->
What it does - plain English
Semaglutide is the active ingredient in Ozempic (FDA-approved for type 2 diabetes) and Wegovy (FDA-approved for chronic weight management). Both are once-weekly injections. It mimics GLP-1 (a hormone your gut releases after eating that tells your brain you're full and helps your body manage blood sugar).
Originally developed for diabetes, it became famous when researchers noticed the weight-loss side effect was unusually large. The newer molecule tirzepatide tends to outperform it on weight loss, but semaglutide has a much longer track record and broader insurance coverage.
It is not a stimulant. It is not a crash diet in a needle. It works by changing how hungry you feel and how your body handles glucose (blood sugar). That is it.
Status
S-tier. The molecule that started the GLP-1 conversation in popular culture. STEP trials (a series of large clinical studies) showed roughly 15% average weight loss over 68 weeks for non-diabetic adults with obesity. SUSTAIN trials established it for type 2 diabetes management.
Critically, the SELECT cardiovascular outcomes trial in 2023 showed a 20% reduction in heart attack, stroke, or cardiovascular death in adults with overweight plus existing cardiovascular disease (heart disease) - even without diabetes. That changed the conversation from "weight loss drug" to "metabolic health drug." Tirzepatide has not yet matched that cardiovascular dataset.
Legal status
Semaglutide is FDA-approved as Ozempic (type 2 diabetes, December 2017), Rybelsus (oral tablet for type 2 diabetes, September 2019), and Wegovy (obesity, June 2021).
Compounded semaglutide (versions made by specialty pharmacies rather than the brand manufacturer) was widely available during FDA-declared drug shortages from 2022 to 2024. The shortage was officially declared resolved in February 2025, which restricts most compounding pharmacies from making it. Some telehealth services still offer compounded versions. Legality varies by state and FDA enforcement posture.
The short version: brand-name Ozempic and Wegovy are fully legal with a prescription. Compounded versions are in a grayer zone than they were two years ago. Ask your provider which path they use.
Where to source
Three paths. Traditional pharmacy with insurance is usually covered with a type 2 diabetes diagnosis, or a BMI (body mass index) of 30-plus for Wegovy. That is the cleanest route if you qualify. Telehealth services (Eden Health, SkinnyRx, Yucca Health, Fridays Health) connect you with a provider who can prescribe and sometimes ship directly. Compounding pharmacies are the third option, now more restricted than before.
Whichever path you take: always ask for a COA (Certificate of Analysis - the lab report that verifies the product contains what it claims, at the right dose). No COA, no buy.
Subscribe below for vendor reviews and price snapshots in the weekly dispatch.
Two studies worth reading
The weight-loss headline
Wilding, J. et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)", NEJM
1,961 adults with overweight or obesity, no diabetes. 14.9% average weight loss at 68 weeks versus 2.4% on placebo. The trial that made Wegovy a household name.
The cardiovascular outcomes pivot
17,604 adults with overweight plus cardiovascular disease, no diabetes. 20% reduction in major cardiovascular events (heart attack, stroke, or cardiovascular death) at five years. The trial that turned semaglutide from a weight loss drug into a metabolic health drug. Most worth reading if you have an aging family member with heart disease history.
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Broken down for normal humans.
Last reviewed · 2026·05·04 · Status reviewed weekly